Solventum Co. (NYSE:SOLV) Holdings Reduced by Wealthspire Advisors LLC

Wealthspire Advisors LLC lessened its holdings in shares of Solventum Co. (NYSE:SOLV) by 22.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,110 shares of the company’s stock after selling 880 shares during the period. Wealthspire Advisors LLC’s holdings in Solventum were worth $205,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in SOLV. Hotchkis & Wiley Capital Management LLC bought a new position in shares of Solventum in the third quarter worth $125,488,000. Trian Fund Management L.P. grew its position in Solventum by 32.9% in the 3rd quarter. Trian Fund Management L.P. now owns 7,126,255 shares of the company’s stock valued at $496,842,000 after buying an additional 1,765,676 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in Solventum during the 3rd quarter valued at about $50,948,000. Nordea Investment Management AB raised its position in shares of Solventum by 189.5% during the 4th quarter. Nordea Investment Management AB now owns 659,887 shares of the company’s stock worth $43,902,000 after buying an additional 431,986 shares in the last quarter. Finally, General American Investors Co. Inc. acquired a new stake in shares of Solventum in the 3rd quarter worth approximately $14,456,000.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on SOLV shares. Bank of America upped their target price on Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a research report on Wednesday. Mizuho initiated coverage on Solventum in a report on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 price objective for the company. Piper Sandler lifted their target price on Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a report on Friday, November 8th. Finally, Morgan Stanley upped their price target on shares of Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and one has given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $71.86.

Solventum Price Performance

SOLV opened at $83.46 on Friday. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. Solventum Co. has a fifty-two week low of $47.16 and a fifty-two week high of $96.05. The business has a 50-day moving average of $72.25 and a 200-day moving average of $69.73.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.